Targeted therapy in non-small-cell lung cancer--is it becoming a reality? (Q37765472)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 15 June 2010

Language	Label	Description	Also known as
English	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?	scientific article published on 15 June 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1 reference

Europe PubMed Central

Targeted therapy in non-small-cell lung cancer--is it becoming a reality? (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Razelle Kurzrock

3

object named as

Razelle Kurzrock

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1

object named as

Filip Janku

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

author name string

David J Stewart

2

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

language of work or name

0 references

publication date

15 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Nature Reviews Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

401-414

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

21 January 2018

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

21 January 2018

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

21 January 2018

Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

21 January 2018

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

21 January 2018

MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

21 January 2018

Lung cancer in never smokers: a review

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Chemotherapy in non-small cell lung cancer: an update of an individual patient data-based meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Detecting an overall survival benefit that is derived from progression-free survival

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Survival of cancer cells is maintained by EGFR independent of its kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Targeted therapy for metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Promoter hypermethylation of resected bronchial margins: a field defect of changes?

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

PIK3CA mutations and copy number gains in human lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

PIK3CA gene amplification in Japanese non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

PIK3CA mutation status in Japanese lung cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

MET as a target for treatment of chest tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Uncommon tumors and exceptional therapies: paradox or paradigm?

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Cancer: the road to Amiens

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/20551945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

1 reference

https://pubmed.ncbi.nlm.nih.gov/20551945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung

1 reference

https://pubmed.ncbi.nlm.nih.gov/20551945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20551945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20551945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/NRCLINONC.2010.64

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37765472&oldid=1414128315"